Effect of Pioglitazone on Thyroid Hormones and IGF-I in Patients with Type 2 Diabetes

Lisa Arnetz,*, Mikael Lantz1, Kerstin Brismar1, Neda Rajamand Ekberg1, Michael Alvarsson1 and Mozhgan Dorkhan2

1Department of Molecular Medicine and Surgery, Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden
2Department of Clinical Sciences, Division of Diabetes & Endocrinology, Lund University, Malmo University Hospital, Sweden

Abstract

**Background:** Thyroid hormones cause insulin resistance. Pioglitazone is a peroxisome proliferator activated receptor gamma (PPARγ) agonist, used as treatment of type 2 diabetes (T2D) to increase insulin sensitivity. PPARs and thyroid hormone receptors (TRs) induce intracellular effects through similar molecular mechanisms, and the former may inhibit activation of the latter. Pioglitazone has been shown to increase eye protrusion, a symptom linked both to disturbed thyroid hormone levels and orbital edema secondary to increased IGF-I.

**Aims:** We investigated whether attenuation of insulin resistance with pioglitazone affects thyroid hormone status and IGF-I.

**Methods:** 48 patients with T2D were treated with pioglitazone for 26 weeks. Thyroid hormones and IGF-I were analyzed before and after treatment.

**Results:** After treatment, free T4 decreased (from 14.2 ± 0.4 to 13.3 ± 0.3 pmol/L, p=0.009) and TSH increased (from 190 ± 200 to 220 ± 200 U/L, p = 0.004). IGF-I also increased (from 0.5 ± 0.2 to 1.0 ± 0.2 SD, p<0.001).

**Conclusion:** Pioglitazone lowers free T4 and increases IGF-I in T2D. This may be due to impeded activation of the TR due to PPAR activation. Increased TSH is most likely secondary to reduce T4 activity. Increased IGF-I may cause orbital edema, as previously noted in patients treated with pioglitazone.

Keywords: Pioglitazone; Type 2 diabetes; IGF-I; Thyroid hormone; TSH; Eye protrusion; PPARγ

Introduction

Changes in thyroid function affect insulin sensitivity, although the studies on the nature of this relationship show somewhat conflicting results. Hyperthyroidism is associated with increased hepatic glucose output, resulting in hyperinsulinemia and insulin resistance [1]. However, insulin resistance is also seen in hypothyroidism [2]. Few studies have examined the effect of improved insulin sensitivity on thyroid hormone status in humans.

The peroxisome proliferation activated receptors (PPARα, β and γ) are a group of nuclear receptors involved in regulation of lipid metabolism and adipose tissue differentiation. Like PPARs, thyroid hormone receptors (TR) belong to the nuclear receptor super family, and act by binding to DNA and modulating gene expression [3]. Both are co-expressed in the brain, liver and adipocytes. In order to bind to DNA and activate transcription, both PPAR and TR require heterodimerization with the retinoid X receptor (RXR). In addition to activating transcription through its own response elements, PPARα is able to selectively down-regulate the transcriptional activity of TR through competitive binding to RXR [4].

PPAR agonists and T3 have been found to act either in a synergistic or opposing manner on various genes involved in lipid metabolism. Their signaling pathways converge through their mutual competition for heterodimerization with RXR. Chu et al. have demonstrated such an interaction in animal studies [5].

Pioglitazone is a PPARγ-activator used in the treatment of type 2 diabetes (T2D). It increases insulin sensitivity in various tissues, partly by redistributing fatty acids from those tissues to the subcutaneous adipose tissue. It also has some agonistic effects on PPARs [6]. In our earlier studies we have noted an increase in eye protrusion in a subgroup of patients with T2D treated with pioglitazone [7]. This phenomenon was more pronounced in patients with lower levels of adiponectin, reflecting a higher degree of insulin resistance. Given the known effects of PPARγ agonists on adipose tissue differentiation, it is possible that treatment induces orbital adipogenesis. This has been indicated in one study on endogenous PPARγ ligands [8]. In a study on insulin resistant women with polycystic ovary syndrome, pioglitazone increased GH but not total IGF-I [9], whereas in our previous studies on patients with T2D total IGF-I was increased [10,11]. Increased levels of IGF-I are associated with edema, especially in the face and orbita [12,13]. Stimulation of the IGF-1 receptor may contribute to ophthalmopathy in Grave’s disease, at least in those patients with elevated levels of TSH-binding inhibitory immunoglobulins [14]. We investigated whether attenuation of insulin resistance with pioglitazone affects thyroid hormone status and IGF-I.

Materials and Methods

The parameters in seen in Table 1 were analyzed before and after six months of treatment with pioglitazone in 48 patients with T2D diabetes [11,15]. Samples for IGF-I and thyroid hormones were stored in -80°C and analyzed in the same run.

*Corresponding author: Lisa Arnetz, Department of Molecular Medicine and Surgery, Karolinska Institutet D2:04 Karolinska University Hospital, 17176 Stockholm, Sweden, Tel: 08-524 800 00; E-mail: lisa.arnetz@ki.se

Received October 21, 2013; Accepted November 29, 2013; Published December 01, 2013

Citation: Arnetz L, Lantz M, Brismar K, Ekberg NR, Alvarsson M, et al. (2013) Effect of Pioglitazone on Thyroid Hormones and IGF-I in Patients with Type 2 Diabetes. Thyroid Disorders Ther 3: 139. doi:10.4172/2167-7948.1000139

Copyright: © Arnetz L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Table 1: Clinical characteristics and laboratory analyses at baseline and after 26 weeks of pioglitazone treatment. Data presented as mean ± SEM except for age and duration of diabetes, presented as range. Δ = change in the variable after treatment compared with baseline, na = not applicable.

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 26</th>
<th>Δ</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (n yrs)</td>
<td>61 (45 – 76)</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Gender (n male: n female)</td>
<td>28:20</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
<td>11 (3 – 30)</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>HbA1c (mmol/mol)</td>
<td>70 ± 7</td>
<td>56 ± 7</td>
<td>-4 ± 7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>90.2 ± 2.2</td>
<td>94 ± 1.2</td>
<td>4 ± 1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.0 ± 0.6</td>
<td>32.3 ± 0.6</td>
<td>1.3 ± 0.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>111 ± 2</td>
<td>112 ± 2</td>
<td>1 ± 1</td>
<td>0.132</td>
</tr>
<tr>
<td>IGF-I (μg/L)</td>
<td>171 ± 6</td>
<td>199 ± 8</td>
<td>28 ± 4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IGF-I (SD)</td>
<td>0.5 ± 0.2</td>
<td>1.0 ± 0.2</td>
<td>0.5 ± 0.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TSH (IU/L)</td>
<td>1.9 ± 0.2</td>
<td>2.2 ± 0.2</td>
<td>0.3 ± 0.2</td>
<td>0.004</td>
</tr>
<tr>
<td>Free T4 (pM/L)</td>
<td>14.2 ± 0.4</td>
<td>13.3 ± 0.3</td>
<td>-0.8 ± 0.3</td>
<td>0.009</td>
</tr>
<tr>
<td>Adiponectin (μg/mL)</td>
<td>6.2 ± 0.4</td>
<td>13.2 ± 0.9</td>
<td>7.1 ± 0.6</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Significance of this Paper

Pioglitazone is a PPARγ agonist used in the treatment of type 2 diabetes, as it increases insulin sensitivity. Treatment is associated with increased eye protrusion, a condition often seen in Graves’ disease. Given this, and the association of IGF-I with orbital edema, we studied the effect of pioglitazone treatment on thyroid hormones and IGF-I. We here report, for the first time, that pioglitazone decreases free T4, secondarily increasing TSH. We also report an increase in IGF-I. Especially the latter finding may explain the increased orbital protrusion seen in patients on pioglitazone therapy.

References
